ASAN FOUNDATION
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1989-06-23
- Employees
- 501
- Market Cap
- -
- Website
- https://ails.amc.seoul.kr
Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT06138769
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Study About Association Between Microbiome, Metabolome and Clinical Characteristics in COPD Patients
Not yet recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 300
- Registration Number
- NCT06101459
CyFluATG in Lower Risk MDS
Phase 2
Active, not recruiting
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Drug: cyclophosphamide, fludarabine, and antithymocyte globulin
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT06098326
- Locations
- 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
HCT With PTCy in Higher-risk MDS
Phase 2
Active, not recruiting
- Conditions
- Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 113
- Registration Number
- NCT06098313
- Locations
- 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 850
- Registration Number
- NCT06086665
- Locations
- 🇰🇷
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of
Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT06064864
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease
Phase 4
Recruiting
- Conditions
- Crohn DiseaseInfliximabMagnetic Resonance Novel Index for Fistula Imaging in Crohn's Disease ScoreTherapeutic Drug MonitoringPerianal Fistula Due to Crohn's Disease
- Interventions
- Drug: TDM-based infliximab intravenous therapyDrug: Standard infliximab intravenous therapy
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 86
- Registration Number
- NCT06051253
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
Phase 3
Recruiting
- Conditions
- Heart Failure With Preserved Ejection FractionTricuspid Regurgitation
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 540
- Registration Number
- NCT06027307
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Yonsei University Medical Center, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Asan Aorta and Peripheral Registry
Recruiting
- Conditions
- Peripheral Artery DiseaseAorta Disease
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 6000
- Registration Number
- NCT06022653
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
The Effect of ERAS on Pancreaticoduodenectomy (v2.0)
Not Applicable
Not yet recruiting
- Conditions
- Borderline Malignancy TumorPeriampullary Cancer
- Interventions
- Other: ERAS perioperative management
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 334
- Registration Number
- NCT06009224
- Locations
- 🇰🇷
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath